METOCLOPRAMIDE IN TARDIVE DYSKINESIA

The effect of single intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) have been compared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia following long term neuroleptic therapy. Tardive dyskinesia rating scores were decreased significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemanani, T.J., Dashputra, P.G., Sarda, R.N.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 1983
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012337/
https://www.ncbi.nlm.nih.gov/pubmed/21847271
_version_ 1782195127991664640
author Hemanani, T.J.
Dashputra, P.G.
Sarda, R.N.
author_facet Hemanani, T.J.
Dashputra, P.G.
Sarda, R.N.
author_sort Hemanani, T.J.
collection PubMed
description The effect of single intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) have been compared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia following long term neuroleptic therapy. Tardive dyskinesia rating scores were decreased significantly (P<0.01) 6 hours after administration of metoclopramide 20 mg and 40 mg when compared with placebo. Reduction of tardive dyskinesia by metoclopramide-a D(2)receptor blocking agent suggest that D(2)receptors may be involved in the mediation of this syndrome.
format Text
id pubmed-3012337
institution National Center for Biotechnology Information
language English
publishDate 1983
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-30123372011-08-16 METOCLOPRAMIDE IN TARDIVE DYSKINESIA Hemanani, T.J. Dashputra, P.G. Sarda, R.N. Indian J Psychiatry Original Article The effect of single intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) have been compared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia following long term neuroleptic therapy. Tardive dyskinesia rating scores were decreased significantly (P<0.01) 6 hours after administration of metoclopramide 20 mg and 40 mg when compared with placebo. Reduction of tardive dyskinesia by metoclopramide-a D(2)receptor blocking agent suggest that D(2)receptors may be involved in the mediation of this syndrome. Medknow Publications 1983 /pmc/articles/PMC3012337/ /pubmed/21847271 Text en Copyright: © Indian Journal of Psychiatry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hemanani, T.J.
Dashputra, P.G.
Sarda, R.N.
METOCLOPRAMIDE IN TARDIVE DYSKINESIA
title METOCLOPRAMIDE IN TARDIVE DYSKINESIA
title_full METOCLOPRAMIDE IN TARDIVE DYSKINESIA
title_fullStr METOCLOPRAMIDE IN TARDIVE DYSKINESIA
title_full_unstemmed METOCLOPRAMIDE IN TARDIVE DYSKINESIA
title_short METOCLOPRAMIDE IN TARDIVE DYSKINESIA
title_sort metoclopramide in tardive dyskinesia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012337/
https://www.ncbi.nlm.nih.gov/pubmed/21847271
work_keys_str_mv AT hemananitj metoclopramideintardivedyskinesia
AT dashputrapg metoclopramideintardivedyskinesia
AT sardarn metoclopramideintardivedyskinesia

Ejemplares similares